AN EARLY ASSESSMENT OF THE GERMAN FEDERAL JOINT COMMISSION RESOLUTIONS OF ADDITIONAL CLINICAL BENEFIT

被引：0
|
作者：
McBride, D. [1 ]
Kilburg, A. [1 ]
Mauskopf, J. [2 ]
机构：
[1] RTI Hlth Solut, Manchester, Lancs, England
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.667
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A311 / A311
页数：1
相关论文
共 50 条
  • [1] Cost-benefit assessment in the German Health Care System: Perspective of the Federal Joint Commission
    Hess, R.
    [J]. GESUNDHEITSWESEN, 2009, 71 : S54 - S55
  • [2] Benefit assessment by the Federal Joint Committee
    Schmedders, M.
    Janatzek, S.
    Zimmer, B.
    [J]. UROLOGE, 2011, 50 (08): : 938 - 943
  • [3] CONDITIONAL RESOLUTIONS IN THE AMNOG EARLY BENEFIT ASSESSMENT
    Assmann, G.
    Schmidt, U.
    Drechsler, M.
    Pfannkuche, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A442 - A442
  • [4] GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT - WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?
    Scheler, E.
    Stratil, A.
    Roxlau, T.
    Bonduelle, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [5] Issues of Additional Benefit Quantification within the Early Benefit Assessment
    Witte, J.
    Greiner, W.
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2013, 18 (05): : 226 - 234
  • [6] Early Benefit Assessment of Pharmaceuticals in Germany: Manufacturers' Expectations versus the Federal Joint Committee's Decisions
    Fischer, Katharina E.
    Stargardt, Tom
    [J]. MEDICAL DECISION MAKING, 2014, 34 (08) : 1030 - 1047
  • [7] Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit
    Kleining, Katrin
    Laufenberg, Jan
    Thrun, Philip
    Ehlert, Dorothee
    Wasem, Juergen
    Bartol, Arne
    [J]. HEALTH ECONOMICS POLICY AND LAW, 2024, 19 (02) : 216 - 233
  • [8] ACCEPTANCE OF INDIRECT COMPARISONS IN THE GERMAN EARLY BENEFIT ASSESSMENT
    Berkemeier, F.
    Bless, H.
    Reindl, S.
    Ballhausen, A.
    Maltz, A.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A663 - A663
  • [9] INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY
    Dintsios, Charalabos-Markos
    Schlenkrich, Sara
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (02) : 196 - 204
  • [10] DATA ON PATIENT-REPORTED OUTCOMES IS NOT A PREREQUISITE FOR ACHIEVING AN ADDITIONAL BENEFIT IN GERMAN EARLY BENEFIT ASSESSMENT OF NEW MEDICINAL PRODUCTS APPROVED FOR DERMATOLOGICAL DISEASES
    Gabriel, M. R.
    Specks, J.
    Duetting, S.
    Damen, D.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S338 - S338
12345